ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, published by BIOLIFE SAS, is a pivotal platform in the fields of Cancer Research, Endocrinology, Immunology, and Physiology, addressing fundamental aspects of biological regulation and homeostasis. Since its inception in 1987, this journal has consistently contributed to the advancement of knowledge, showcasing innovative research and breakthroughs that are instrumental for professionals, researchers, and students alike. Although categorized in the Q4 quartile across multiple disciplines, the journal offers a unique perspective that encourages exploration into underrepresented areas, underscoring its role in fostering scientific dialogue and collaboration. With ISSN 0393-974X and E-ISSN 1724-6083, the journal remains a crucial resource for those invested in understanding the complexities of homeostatic agents and their implications in health and disease. Based in Silva Marina, Italy, it invites contributions that broaden the horizons of contemporary biomedical research.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

Biomolecules & Therapeutics is a prominent journal published by the Korean Society of Applied Pharmacology, dedicated to advancing knowledge in the fields of Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. With an ISSN of 1976-9148 and an E-ISSN of 2005-4483, this journal serves as a vital platform for researchers and professionals to disseminate their findings from 2008 through 2024. Ranking in the Q2 category across multiple relevant fields, including Pharmacology and Drug Discovery, and consistently placing in the 60th to 70th percentiles in Scopus rankings, Biomolecules & Therapeutics exemplifies a commitment to high-quality research and scientific integrity. Although it operates on a traditional access model, readers can be assured of the journal's rigorous peer-review process, ensuring that published articles contribute meaningfully to ongoing discourse in pharmacological and biochemical research. Located in Seoul, South Korea, the journal stands at the forefront of innovation in healthcare, making it an essential resource for academics, students, and industry professionals alike.

Russian Journal of Bioorganic Chemistry (ISSN: 1068-1620, E-ISSN: 1608-330X), published by MAIK Nauka/Interperiodica/Springer, serves as a vital resource for researchers and professionals in the fields of bioorganic chemistry, biochemistry, and organic chemistry. With a focus on the integration of organic chemistry principles with biological processes, this journal aims to disseminate significant findings and advancements from both theoretical and practical perspectives. Although currently not open access, the journal retains a dedication to high-quality, peer-reviewed content, contributing to its reputation within the academic community. The 2023 Scopus rankings position it within the Q4 category for both biochemistry and organic chemistry, indicating its critical niche within these disciplines amid a competitive landscape. Since its inception in 1996, the journal has continued to evolve, providing enriching insights and fostering collaborations among scholars and practitioners alike, with publication converging up to the year 2024. By exploring complex biomolecular interactions and the synthesis of biologically relevant compounds, the Russian Journal of Bioorganic Chemistry remains a significant platform for advancing knowledge and innovation in the life sciences.